Updates are available Correction dated 2021-09-03
Click to view Correction: https://doi.org/10.1186/s10020-021-00354-8
-
Authors
Wang, Mao
Gauthier, Alex G.
Kennedy, Thomas P.
Wang, Haichao
Velagapudi, Uday Kiran
Talele, Tanaji T.
Lin, Mosi
Wu, Jiaqi
Daley, LeeAnne
Yang, Xiaojing
Patel, Vivek
Mun, Sung Soo
Ashby, Charles R. Jr.
Mantell, Lin L. http://orcid.org/0000-0003-0367-1507
-
Funding
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (HL093708)
St. John’s University
- License Information
-
More Information
Article History
Received: 5 December 2020
Accepted: 21 June 2021
First Online: 16 July 2021
Change Date: 3 September 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s10020-021-00354-8
Declarations
:
: The study was reviewed and approved by the IACUC at St. John’s University.
: All authors read and approved the manuscript.
: Thomas Kennedy is the inventor of 2-O, 3-O desulfated heparin and holds Founders Stock in Cantex Pharmaceuticals, a developer of this compound. Tanaji Talele is a co-founder of Hysplex LLC.
